New Test Detects Both Parvovirus B19 and Hepatitis A in Plasma
By LabMedica International staff writers Posted on 05 Apr 2015 |
A CE-marked molecular duplex test, for use on Cobas 6800/8800 systems, helps increase safety of human blood and plasma products by simultaneous screening for parvovirus B19 (B19V) and hepatitis A virus (HAV).
Nucleic acid amplification testing (NAT) enables detection of active viral infections earlier than conventional immunoassays. Roche (Basel, Switzerland) now offers the “cobas DPX” real-time PCR test for use on its cobas 6800/8800 systems, expanding the menu of these latest diagnostic platforms with next-generation donor-screening assays.
“Roche is committed to providing the broadest coverage and most efficient blood and plasma screening tests to ensure the highest safety for patients,” said Paul Brown, head of Roche Molecular Diagnostics, “Introducing cobas DPX to the cobas 6800/8800 Systems is an important step toward that goal, complementing our current donor-screening tests for the detection of HIV, HCV, HBV, WNV and HEV.” Performing NAT with cobas DPX increases the processing efficiency of donations while preserving high safety standards for plasma products. Cobas DPX enables blood and plasma testing centers to quickly identify and remove HAV-contaminated units, while simultaneously minimizing the B19V burden in plasma pools.
The cobas 6800 and 8800 systems (medium and high throughput models, respectively) are automated solutions designed for more efficient blood-donor screening, viral load monitoring, women’s health and microbiology testing. Both systems enable long “work-away” (minimal user-interaction) times, and allow for mixed batching, enabling up to three tests in the same run with no pre-sorting required.
cobas DPX and cobas 6800/8800 systems are available where the CE-marking is recognized.
Related Links:
Roche
cobas 6800/8800 systems
Nucleic acid amplification testing (NAT) enables detection of active viral infections earlier than conventional immunoassays. Roche (Basel, Switzerland) now offers the “cobas DPX” real-time PCR test for use on its cobas 6800/8800 systems, expanding the menu of these latest diagnostic platforms with next-generation donor-screening assays.
“Roche is committed to providing the broadest coverage and most efficient blood and plasma screening tests to ensure the highest safety for patients,” said Paul Brown, head of Roche Molecular Diagnostics, “Introducing cobas DPX to the cobas 6800/8800 Systems is an important step toward that goal, complementing our current donor-screening tests for the detection of HIV, HCV, HBV, WNV and HEV.” Performing NAT with cobas DPX increases the processing efficiency of donations while preserving high safety standards for plasma products. Cobas DPX enables blood and plasma testing centers to quickly identify and remove HAV-contaminated units, while simultaneously minimizing the B19V burden in plasma pools.
The cobas 6800 and 8800 systems (medium and high throughput models, respectively) are automated solutions designed for more efficient blood-donor screening, viral load monitoring, women’s health and microbiology testing. Both systems enable long “work-away” (minimal user-interaction) times, and allow for mixed batching, enabling up to three tests in the same run with no pre-sorting required.
cobas DPX and cobas 6800/8800 systems are available where the CE-marking is recognized.
Related Links:
Roche
cobas 6800/8800 systems
Latest Microbiology News
- Integrated Solution Ushers New Era of Automated Tuberculosis Testing
- Automated Sepsis Test System Enables Rapid Diagnosis for Patients with Severe Bloodstream Infections
- Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases
- Clinical Decision Support Software a Game-Changer in Antimicrobial Resistance Battle
- New CE-Marked Hepatitis Assays to Help Diagnose Infections Earlier
- 1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens
- Mouth Bacteria Test Could Predict Colon Cancer Progression
- Unique Metabolic Signature Could Enable Sepsis Diagnosis within One Hour of Blood Collection
- Groundbreaking Diagnostic Platform Provides AST Results With Unprecedented Speed
- Simple Blood Test Combined With Personalized Risk Model Improves Sepsis Diagnosis
- Blood Analysis Predicts Sepsis and Organ Failure in Children
- TB Blood Test Could Detect Millions of Silent Spreaders
- New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours
- New Tuberculosis Test to Expand Testing Access in Low- and Middle-Income Countries
- Rapid Test Diagnoses Tropical Disease within Hours for Faster Antibiotics Treatment
- Rapid Molecular Testing Enables Faster, More Targeted Antibiotic Treatment for Pneumonia